regulatory
confidence high
sentiment negative
materiality 0.65
Tivic Health receives Nasdaq delisting notice for bid price below $1.00 for 33 days
Valion Bio, Inc.
- Received Nasdaq deficiency letter on June 28, 2024 for non-compliance with minimum bid price requirement.
- Closing bid price below $1.00 per share for 33 consecutive business days.
- 180-day cure period ends December 26, 2024; must close at or above $1.00 for 10 consecutive days.
- If not compliant by deadline, may request a second 180-day period if other listing standards are met.
- Listing remains fully effective during cure period; company evaluating options to regain compliance.